[
  {
    "ts": null,
    "headline": "Why Merck Is A Better Dividend Stock Than Gilead Sciences",
    "summary": "Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.",
    "url": "https://finnhub.io/api/news?id=3cadfa7a66dbe4895300ba5134ba960e57d6f80120e8fcac3740403e49c60606",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752678509,
      "headline": "Why Merck Is A Better Dividend Stock Than Gilead Sciences",
      "id": 135970484,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1187806357/image_1187806357.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.",
      "url": "https://finnhub.io/api/news?id=3cadfa7a66dbe4895300ba5134ba960e57d6f80120e8fcac3740403e49c60606"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment",
    "summary": "As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.",
    "url": "https://finnhub.io/api/news?id=454392830c12868361ca716b78700379f819251452d415d95465e164930bb5d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752636849,
      "headline": "Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment",
      "id": 135965519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.",
      "url": "https://finnhub.io/api/news?id=454392830c12868361ca716b78700379f819251452d415d95465e164930bb5d3"
    }
  },
  {
    "ts": null,
    "headline": "GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm",
    "summary": "LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences,...",
    "url": "https://finnhub.io/api/news?id=2ca4b18ec85cda5650a7ca54928a655abdd654d26840568f33da77204dea626e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752635586,
      "headline": "GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm",
      "id": 135962024,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences,...",
      "url": "https://finnhub.io/api/news?id=2ca4b18ec85cda5650a7ca54928a655abdd654d26840568f33da77204dea626e"
    }
  }
]